The latest data from the Phase II SCOPE trial in advanced melanoma will be presented at ESMO IO. Cohort 1 (SCIB1) and Cohort 3 (iSCIB1+) evaluate the addition of SCIB1/iSCIB1+ to double checkpoint inhibitors (CPIs) nivolumab and ipilimumab, now considered SoC (standard of care). Highly promising data to date, which could redefine SoC, has already prompted the selection of next generation iSCIB1+ for the registrational Phase III trial being planned.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
